Dr. Paul Wheatley-Price, MD
Claim this profileThe Ottawa Hospital PHASE 2
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
12 drugs studied
Area of expertise
1Lung Cancer
Stage IV
EGFR negative
EGFR positive
2Non-Small Cell Lung Cancer
Stage IV
EGFR negative
EGFR positive
Affiliated Hospitals
Clinical Trials Paul Wheatley-Price, MD is currently running
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting1 award Phase 1 & 27 criteria
Osimertinib Rechallenge
for Lung Cancer
This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy. The repeat of osimertinib following previous treatment failure is investigational, although supported by scientific rationale. The dosing and scheduling of osimertinib follows its use in approved settings. The investigators examine its tolerability and efficacy in this setting to ensure osimertinib is a safe third-line option for patients with Epidermal Growth Factor Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer(aNSCLC).
Recruiting1 award Phase 29 criteria
More about Paul Wheatley-Price, MD
Clinical Trial Related6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Paul Wheatley-Price, MD has experience with
- Repotrectinib (TPX-0005)
- Osimertinib
- Platinum + Pemetrexed
- Cobolimab
- Docetaxel
- Dostarlimab
Breakdown of trials Paul Wheatley-Price, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Uterine Tumors
Metastatic Tumor
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paul Wheatley-Price, MD specialize in?
Paul Wheatley-Price, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR negative.
Is Paul Wheatley-Price, MD currently recruiting for clinical trials?
Yes, Paul Wheatley-Price, MD is currently recruiting for 2 clinical trials in Ottawa Ontario. If you're interested in participating, you should apply.
Are there any treatments that Paul Wheatley-Price, MD has studied deeply?
Yes, Paul Wheatley-Price, MD has studied treatments such as Repotrectinib (TPX-0005), Osimertinib, Platinum + Pemetrexed.
What is the best way to schedule an appointment with Paul Wheatley-Price, MD?
Apply for one of the trials that Paul Wheatley-Price, MD is conducting.
What is the office address of Paul Wheatley-Price, MD?
The office of Paul Wheatley-Price, MD is located at: The Ottawa Hospital PHASE 2, Ottawa, Ontario K1H 8L6 Canada. This is the address for their practice at the The Ottawa Hospital PHASE 2.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.